@brettfirdman post

Audited July 19, 2026 · Post from Dec 16, 2025

Supported

The NAD+ claim is supported by strong preclinical evidence (mouse models showing improvements in energy metabolism, insulin sensitivity, and physical activity) and active Phase 2 human trials investigating NAD augmentation for age-related disease. The GHK-Cu claim cannot be assessed because relevant abstracts were referenced but not provided for evaluation. To complete the GHK-Cu analysis, retrieve and review the Pickart & Margolina (2018) review and available PubMed abstracts on GHK-Cu and skin/collagen biology.

Share this audit

One link — full verdict, every claim, and PubMed citations included.

peptiq.io/check/1323eaeb

Shareable link includes the full verdict, claims, and PubMed citations.

Post captionshow

On my way to something new… my peptide era at @medlounge_co 🧬✨ But first—coffee. Always coffee ☕️ Everyone’s talking about peptides and I was like… okay, but what are we actually talking about? So I got curious, did the labs, and here we are. Starting at square one + sharing it all. Stay tuned 🤍

Video transcriptshow

Hi friends, on my way to something new today, my peptide journey. But first, coffee, obviously. Everyone is talking about peptides and I'll be honest, I had no idea what half of it meant, but as a lady in her 40s, I have been very curious. I paid a visit to Medlounge, which everyone in Orange County seems to be going to. We started with full vitals and a blood panel and here I am back with my resu

Show full video transcript

lts and their medical team and turns out i could use a little support so we're starting with nad and the super popular ghk copper glow stack new year new me can wait you feel me i am so excited to share this journey and i hope you will stay tuned because i am going to share everything

Show less

Claim breakdown

2 claims
1

NAD (nicotinamide adenine dinucleotide) provides support.

Supported

Multiple human clinical trials are actively recruiting to test NAD augmentation for diabetes kidney disease and other conditions (NCT05759468, NCT06313203). Peer-reviewed literature demonstrates that NAD+ decline is causally linked to aging-associated diseases, and that restoring NAD+ levels in mice mitigates age-related physiological decline — including improved energy metabolism, insulin sensitivity, and physical activity (Covarrubias et al., Nat Rev Mol Cell Biol 2021; Mills et al., Cell Metab 2016). The concept of NAD+ providing cellular support is backed by robust preclinical evidence and emerging human trials.

2

GHK copper (GHK-Cu) provides glow.

No Evidence

No human clinical trials were identified for GHK-Cu and skin 'glow' specifically. Internal PeptIQ knowledge indicates GHK-Cu literature exists (Pickart & Margolina 2018; PubMed skin research database), but the abstracted evidence from that search was not provided in this analysis, making independent verification impossible. The claim cannot be evaluated against published literature without access to those abstracts.

Audit another post

Instagram, TikTok, X, Reddit, or paste text directly.

New audit

Track your protocols

Dosing, logging, and reminders in the app.

Get the app

This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.

Report an error